First Trust NYSE Arca Biotechnology Index Fund
FBT
249 hedge funds and large institutions have $707M invested in First Trust NYSE Arca Biotechnology Index Fund in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 59 increasing their positions, 87 reducing their positions, and 21 closing their positions.
24% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 21
2% more funds holding
Funds holding: 245 → 249 (+4)
0.16% more ownership
Funds ownership: 49.5% → 49.65% (+0.16%)
1% less capital invested
Capital invested by funds: $717M → $707M (-$9.89M)
32% less repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 87
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$10.8M |
| 2 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$8.88M |
| 3 |
MML Investors Services
Springfield,
Massachusetts
|
+$4.22M |
| 4 |
NA
Navellier & Associates
Reno,
Nevada
|
+$3.57M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$2.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$12.3M |
| 2 |
JAWM
J. Arnold Wealth Management
Youngstown,
Ohio
|
-$11.4M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$11.1M |
| 4 |
AAS
Ameritas Advisory Services
Lincoln,
Nebraska
|
-$7.28M |
| 5 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$2.96M |
FBT Hedge Fund Activity: Q2 2023 in Review
249 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in First Trust NYSE Arca Biotechnology Index Fund (FBT) for Q2 2023, worth a combined $707M — down 1.4% from $717M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new FBT positions and 21 closed out — a net gain of 5 holders — while 59 added to existing stakes and 87 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $10.8M. The largest seller was UBS Group, cutting an estimated $12.3M.
- 249 institutional investors held First Trust NYSE Arca Biotechnology Index Fund (FBT) as of Q2 2023, up from 245 in Q1 2023.
- Funds reported $707M of First Trust NYSE Arca Biotechnology Index Fund stock for Q2 2023, down 1.4% quarter-over-quarter.
- 26 funds opened new First Trust NYSE Arca Biotechnology Index Fund positions in Q2 2023 and 21 closed out, a net change of +5 holders.
- The largest First Trust NYSE Arca Biotechnology Index Fund buyer in Q2 2023 was Morgan Stanley, an estimated $10.8M added.
- The largest First Trust NYSE Arca Biotechnology Index Fund seller in Q2 2023 was UBS Group, an estimated $12.3M sold.
Based on aggregated 13F filings for Q2 2023.